Tag: Intact vascular
Philips to expand its image-guided therapy portfolio through acquisition of Intact...
Royal Philips today announced that it has signed an agreement to acquire Intact Vascular. According to a press release, Intact Vascular will enhance Philips’...
Intact Vascular announces positive one-year data from TOBA II BTK clinical...
Intact Vascular announced the positive one-year results from its Tack optimised balloon angioplasty (TOBA) II BTK clinical trial during the 2020 Vascular Interventional Advances (VIVA)...
TOBA III clinical trial results published in the Journal of Vascular...
Intact Vascular has announced the peer-reviewed publication of its Tack optimised balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery.
The multi-centre, single-arm,...
First US commercial use of Tack Endovascular System (4F) in BTK...
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the USA. Notably the first FDA-approved...
First US commercial use of Tack Endovascular System in BTK arteries...
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the USA. Notably the first FDA-approved...
Tack Endovascular System receives FDA approval for below-the-knee post-angioplasty dissection repair
Intact Vascular has received US Food and Drug Administration (FDA) approval for the Tack Endovascular System (4F), a novel, minimal metal implant for precision...
Intact Vascular expands Tack Endovascular System portfolio offering
Intact Vascular has announced US Food and Drug Administration (FDA) pre-market approval (PMA) for the expansion of its Tack Endovascular System (6F) portfolio. The...
VIVA 2019: TOBA II BTK meets primary safety and efficacy endpoints...
It was announced today at the 2019 Vascular Interventional Advances conference (VIVA) (4–7 November, Las Vegas, USA) that, through six months, TOBA II BTK...
Real-world use of the Tack Endovascular System published
Intact Vascular has announced the peer-reviewed publication, “Practical applications of Tack implants for infrainguinal dissection repair: A single-centre experience” currently available online, with...
Tack Endovascular System launches in the USA, first commercial use announced
Intact Vascular has announced the first commercial use of its Tack Endovascular System in multiple sites across the USA. Recently FDA-approved for above-the-knee interventions,...
Identifying and repairing dissections that matter
Marianne Brodmann (Graz, Austria) quizzes Michael Lichternberg (Arnsberg, Germany) at LINC 2019 on his choice of tools to identify and repair dissections in both...
Tack Endovascular System launches in the EU with first commercial use...
The first commercial use of the Tack Endovascular System (Intact Vascular) has taken place in multiple hospitals within Germany. A novel therapy for dissection...
TOBA II BTK clinical trial completes enrolment
The Tack Optimised Balloon Angioplasty II below-the-knee (TOBA II BTK) clinical trial has successfully completed enrolment, ahead of schedule. This study, sponsored by Intact...
TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for...
Thomas Zeller (Bad Krozingen, Germany) delves into data and design of the TOBA II (Tack Optimized Balloon Angioplasty II) trial with principal investigator William...
TOBA II trial meets primary and secondary endpoints at one-year
The Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial has successfully achieved both primary and secondary endpoints. One year results from the TOBA...
Intact Vascular announces presentation of TOBA II pivotal data
Intact Vascular has announced that data from its Tack Optimized Balloon Angioplasty (TOBA) II pivotal study will be presented as a late-breaking clinical trial...
Tack Endovascular System secures US$20 million in premarket approval funding
Intact Vascular, a developer of medical devices for minimally invasive peripheral vascular procedures, has announced that it closed a Series C financing totaling US$20 million....
TOBA BTK trial study publishes one-year results for Tack endovascular system
The TOBA BTK (Tack Optimized Balloon Angioplasty Below the Knee) clinical trial results have recently been published in Catheterization and Cardiovascular Intervention. The multicentre...
TOBA single-centre trial shows 24-month patency rate of 87.5%
Positive single-centre 24-month results from Intact Vascular’s TOBA (Tack optimised balloon angioplasty) clinical study were presented at the 2017 VEITHsymposium 2017 (14–18 November, New York City, USA) by...
Intact Vascular announces enrolment of first European patient in TOBA II...
Intact Vascular’s TOBA II BTK (Tack optimized balloon angioplasty II below the knee) clinical trial has commenced enrolment in Europe, with the first patient treated by Marianne Brodmann and Peter Reif...
FDA approves six-month primary endpoint for Tack endovascular system in below-the-knee...
The US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint in Intact Vascular’s TOBA II...
Intact Vascular appoints Howard Rosen as vice president of marketing and...
Howard Rosen has joined Intact Vascular’s executive management team as vice president of marketing and business development. In this position, Rosen will lead the...
Intact Vascular completes enrolment in TOBA II clinical trial
Intact Vascular’s TOBA II (Tack optimized balloon angioplasty II) clinical trial has completed enrolment. A total of 210 patients have been enrolled in TOBA II at 33 sites...
Using the Tack endovascular system to treat vessel dissection
At LINC 2017 Vascular News spoke to Peter Schneider (Kaiser Foundation Hospital, Honolulu, Hawaii, USA) about the Tack endovascular system (Intact Vascular), an implant designed to repair...
TOBA II BTK clinical trial commences enrolment with first implant of...
Intact Vascular’s TOBA II BTK (Tack optimised balloon angioplasty II below the knee) clinical trial has commenced enrolment, with the first patient treated by Joseph Cardenas at Yuma Regional Hospital and...
Intact Vascular closes on additional funding to advance development of Tack...
Current Intact Vascular investors—New Enterprise Associates, Quaker Partners and HIG BioHealth Partners—have exercised their right to invest additional capital as part of the company’s...
TOBA study results demonstrate 76.4% 12-month primary patency and 89.5% freedom...
The one-year results from Intact Vascular’s Tack Optimized Balloon Angioplasty (TOBA) clinical study have been published in the Journal of Vascular Surgery.
The TOBA study...
